Cancer drugs are high growth items for the Pharmaceutical Benefits Scheme, a new report shows. In its expenditure summary for the last year, the PBS lists ruxolitnib (Jakavi), enzalutamide (Xtandi) and trametinib (Mekinist) among the top 20 drugs for growth in costs to the government. Ruxolitinib, which is licensed for the treatment of patients with primary myelofibrosis ...
Three cancer drugs push PBS cost growth
By Michael Woodhead
19 Jan 2018